CTLA4 enhances the osteogenic differentiation of allogeneic human mesenchymal stem cells in a model of immune activation.
Braz J Med Biol Res
; 48(7): 629-36, 2015 Jul.
Article
en En
| MEDLINE
| ID: mdl-26017342
ABSTRACT
Allogeneic mesenchymal stem cells (allo-MSCs) have recently garnered increasing interest for their broad clinical therapy applications. Despite this, many studies have shown that allo-MSCs are associated with a high rate of graft rejection unless immunosuppressive therapy is administered to control allo-immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA4) is a co-inhibitory molecule expressed on T cells that mediates the inhibition of T-cell function. Here, we investigated the osteogenic differentiation potency of allo-MSCs in an activated immune system that mimics the in vivo allo-MSC grafting microenvironment and explored the immunomodulatory role of the helper T cell receptor CTLA4 in this process. We found that MSC osteogenic differentiation was inhibited in the presence of the activated immune response and that overexpression of CTLA4 in allo-MSCs suppressed the immune response and promoted osteogenic differentiation. Our results support the application of CTLA4-overexpressing allo-MSCs in bone tissue engineering.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Osteogénesis
/
Linfocitos T
/
Terapia de Inmunosupresión
/
Trasplante de Células Madre Mesenquimatosas
/
Células Madre Mesenquimatosas
/
Antígeno CTLA-4
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Braz J Med Biol Res
Año:
2015
Tipo del documento:
Article